Dr. K. Kiran Kumar

Dr. K. Kiran Kumar

MD, DNB (Radiation Therapy) (Radiation Oncology)

Sr. Consultant Radiation Oncologist

Languages:
English, Hindi, Telugu
Med Reg No:
46981

Day time OPD:
MON - SAT : 12:00 PM - 04:00 PM

Location:
Hitec CitySomajiguda

Dr. K. Kiran Kumar is a Consultant Radiation Oncologist at Yashoda Hospitals, Somajiguda, with over 15 years of experience.

Educational Qualifications

  • MD, DNB (Radiation Therapy)

Experience

  • 2008-Present: Consultant Radiation Oncologist, Yashoda Hospitals, Somajiguda
  • 2007-2008: Registrar, Department of Radiation Oncology

Services offered

  • Brachytherapy (Internal Radiation Therapy)
  • External Beam Radiation for Prostate Cancer
  • Radiation Oncology
  • Advanced Techniques (SBRT, IMRT, IGRT)
  • Cancer Screening (Preventive)
  • SBRT/SABR (Stereotactic Body Radiotherapy) for Cancerous Tumours
  • Stereotactic Radiosurgery (SRS) for Brain & Spine Tumours
  • External Beam Radiotherapy (EBRT)
  • Image Guided Radiotherapy (IGRT)
  • Teleradiotherapy
  • Accelerated Partial Breast Radiotherapy
  • Hormone Therapy for Breast Cancer
  • Hormone Therapy for Prostate Cancer
  • Pap Smear

Special Interest and Expertise

  • Rapid Arc Technique/SRS/SRT

Select preferred date and time to continue to book an appointment

Sun
Mon 23 Dec
Tue 24 Dec
Wed 25 Dec
Thu 26 Dec
Fri 27 Dec
Sat 28 Dec
Sun
Mon 30 Dec
Tue 31 Dec
Wed 01 Jan
Thu 02 Jan
Fri 03 Jan
Sat 04 Jan
Sun
Mon 06 Jan
Tue 07 Jan
Wed 08 Jan
Thu 09 Jan
Fri 10 Jan
Sat 11 Jan
Sun
Mon 13 Jan
Tue 14 Jan
Wed 15 Jan
Thu 16 Jan
Fri 17 Jan
Sat 18 Jan
Sun
Mon 20 Jan
Tue 21 Jan
  • ARIO
  • IMA
  • ESMO
  • Principal Investigator in Trial no 1200.161, Trial title-A randomized, open-label, phase III study to evaluate the efficacy and safety of oral afatinib versus intravenous methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who have progressed after platinum-based therapy
  • Principal Investigator trial number: 1200:131 Trial title-LUX-Head and Neck 2: randomised, double blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib as adjuvant therapy after chemo-radiotherapy in primary unresected patients with stage III, IVa, or IVb loco-regionally advanced head and neck squamous cell carcinoma
  • Title: P276-00/64/11 “A Multicenter, Phase II/III study to assess radiation induced mucositis in subjects with locally advanced squamous cell carcinoma of the head and neck, administered cisplatin and radiation with or without P276-00
  • Title NETU08-18: A phase III multicenter, randomized, double-blind, double-dummy, active-controlled, parallel group study of the efficacy and safety of oral netupitant administered in combination with palonosetron and dexamethasone compared to oral palonosetron and dexamethasone for the prevention of nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy
  • Title: PALO10-01: Single dose, multicenter, randomized, double-blind, double-dummy, parallel group study to assess the efficacy and safety of oral palonosetron 0.50 mg compared to I.V palonosetron 0.25mg administered with dexamthasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving highly emetogenic cisplatin-based chemotherapy

Testimonial for Dr. K. Kiran Kumar

Mr. Abdul Shafie

Patient Location: Sudan

I am facing problems with mycosis fungoides and it affected my skin, the rash...

Read more